Navigation Links
Roche Diagnostics Introduces Full Line of 9-Minute STAT Assays for Cardiac Biomarker Testing on cobas 6000 Analyzer Series

INDIANAPOLIS, Sept. 16 /PRNewswire/ -- Roche Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has introduced a complete battery of STAT immunoassays for cardiac biomarker testing on the cobas® 6000 analyzer series, an integrated system designed for diagnostic labs with medium testing volumes. With a 9-minute duration, the assays are faster than any other cardiac immunoassay tests currently available on an integrated platform and enable labs to deliver results to doctors treating cardiac patients in about half the time of standard Roche tests. The tests complement a line of existing STAT cardiac assays for Roche's stand-alone platform, the cobas 4000 series.

"In critical care environments that require rapid decision-making, this new line of STAT assays can help healthcare facilities meet current cardiac care turnaround time guidelines," said Hans-Juergen Loyda, Ph.D., MBA, director of clinical development and education at Roche Diagnostics Corporation. "Making the tests available on the cobas 6000 series gives labs the option to run Roche STAT assays on either stand-alone or integrated platforms."

The new 9-minute STAT immunoassay tests include troponin T, troponin I, CK-MB, myoglobin and NT-proBNP and run on the cobas e 601 analyzer, part of the cobas 6000 analyzer series, an integrated platform that offers both clinical chemistry and immunoassay testing. The STAT tests are virtually equivalent to Roche's 18-minute tests in performance, precision and sensitivity.

The cardiac STAT assays can all be run with one simple blood draw via the Roche OneTUBE solution, which consists of a single lithium heparin tube that can be run on any of Roche's integrated platforms. By allowing a single technician to process a single draw from a single point of entry instead of drawing multiple tubes for cardiac tests on multiple analyzers, the OneTUBE solution helps to simplify sample handling and reduce the need for sample splitting.

About Cardiac Critical Care GuidelinesThe National Association of Clinical Biochemistry (NACB) recommends that cardiac biomarker testing should have a turnaround time (TAT) of less than 60 minutes – optimally 30 minutes.(1) A conventional biomarker panel for patients presenting with shortness of breath includes troponin, CK-MB, myoglobin, D-dimer and NT-proBNP.(2) In addition, a cardiac biomarker test TAT of 30 minutes or less is required for a facility to be accredited as a Chest Pain Center by the Society of Chest Pain Centers.(3)

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: or

All trademarks used or mentioned in this release are protected by law.

1 Storrow AB, Apple FS, Wu AH, Jesse R, Francis G, Christenson RH. Use of cardiac biomarkers for acute coronary syndromes. In: Laboratory medicine practice guidelines: evidence-based practice for point-of-care testing. Washington (DC): National Academy of Clinical Biochemistry (NACB); 2006. p. 13-20. Accessed September 2010 at:

2 Singer AJ, Thode HC Jr, Green GB et al. The incremental benefit of a shortness-of-breath biomarker panel in emergency department patients with dyspnea. Acad Emerg Med. 2009 Jun;16(6):488-94.

3 Peacock WF, Fonarow GC, Ander DS et al. Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient. A report from the society of chest pain centers acute heart failure committee. Acute Cardiac Care. 2009;11:1,3-42.For further information, please contact: Betsy Cox Director, Corporate CommunicationsRoche Diagnostics CorporationIndianapolis, IN(317)

SOURCE Roche Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Roche Receives FDA Clearance for U.S. Launch of cobas 8000 Modular Analyzer Series for High-Volume Laboratory Testing
2. New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
3. caprotec bioanalytics Announces the Successful Completion of a Collaborative Research Project With Roche
4. Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
5. Roche Holds Seventh Annual Childrens Walk
6. Roche Symposium Showcases Accomplishments of Next Generation of Chemists
7. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
8. Roche Women Honored as 2010 TWIN Awardees
9. Roches Quinn Honored as 2010 HBA Rising Star
10. Roche Announces Joint Initiative to Train Healthcare Workers in Africas Fight Against Cancer
11. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):